These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23828406)

  • 21. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis.
    Rabassa ME; Croce MV; Pereyra A; Segal-Eiras A
    BMC Cancer; 2006 Oct; 6():253. PubMed ID: 17064405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer.
    Croce MV; Isla-Larrain MT; Rua CE; Rabassa ME; Gendler SJ; Segal-Eiras A
    J Histochem Cytochem; 2003 Jun; 51(6):781-8. PubMed ID: 12754289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
    Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
    Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.
    Adluri S; Gilewski T; Zhang S; Ramnath V; Ragupathi G; Livingston P
    Br J Cancer; 1999 Apr; 79(11-12):1806-12. PubMed ID: 10206297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses.
    von Mensdorff-Pouilly S; Kinarsky L; Engelmann K; Baldus SE; Verheijen RH; Hollingsworth MA; Pisarev V; Sherman S; Hanisch FG
    Glycobiology; 2005 Aug; 15(8):735-46. PubMed ID: 15814824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue.
    Croce MV; Isla-Larrain M; Remes-Lenicov F; Colussi AG; Lacunza E; Kim KC; Gendler SJ; Segal-Eiras A
    Histol Histopathol; 2006 Aug; 21(8):849-55. PubMed ID: 16691537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissues or cells.
    Hinoda Y; Takahashi T; Hayashi T; Suwa T; Makiguchi Y; Itoh F; Adachi M; Imai K
    J Gastroenterol; 1998 Apr; 33(2):164-71. PubMed ID: 9605944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.
    von Mensdorff-Pouilly S; Gourevitch MM; Kenemans P; Verstraeten AA; Litvinov SV; van Kamp GJ; Meijer S; Vermorken J; Hilgers J
    Eur J Cancer; 1996 Jul; 32A(8):1325-31. PubMed ID: 8869094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women.
    Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T
    Breast Cancer Res Treat; 2005 Aug; 92(3):223-30. PubMed ID: 16155793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer.
    Gheybi E; Amani J; Salmanian AH; Mashayekhi F; Khodi S
    Tumour Biol; 2014 Nov; 35(11):11489-97. PubMed ID: 25128064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction.
    de Cremoux P; Extra JM; Denis MG; Pierga JY; Bourstyn E; Nos C; Clough KB; Boudou E; Martin EC; Müller A; Pouillart P; Magdelénat H
    Clin Cancer Res; 2000 Aug; 6(8):3117-22. PubMed ID: 10955792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.
    Burford B; Gentry-Maharaj A; Graham R; Allen D; Pedersen JW; Nudelman AS; Blixt O; Fourkala EO; Bueti D; Dawnay A; Ford J; Desai R; David L; Trinder P; Acres B; Schwientek T; Gammerman A; Reis CA; Silva L; Osório H; Hallett R; Wandall HH; Mandel U; Hollingsworth MA; Jacobs I; Fentiman I; Clausen H; Taylor-Papadimitriou J; Menon U; Burchell JM
    Br J Cancer; 2013 May; 108(10):2045-55. PubMed ID: 23652307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls.
    Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; van Zanten-Przybysz I; Hummel P; Nijman HW; Kenemans P; Hilgers J
    Cancer Immunol Immunother; 1999 Apr; 48(1):47-55. PubMed ID: 10235488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer.
    Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K
    J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignancy-induced autoimmunity to MUC1: initial antibody characterization.
    Graves CR; Robertson JF; Murray A; Price MR; Chapman CJ
    J Pept Res; 2005 Dec; 66(6):357-63. PubMed ID: 16316451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
    Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
    Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival.
    Kurtenkov O; Klaamas K; Mensdorff-Pouilly S; Miljukhina L; Shljapnikova L; Chuzmarov V
    Acta Oncol; 2007; 46(3):316-23. PubMed ID: 17450466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular evolution of specific human antibody against MUC1 mucin results in improved recognition of the antigen on tumor cells.
    Persson J; Bäckström M; Johansson H; Jirström K; Hansson GC; Ohlin M
    Tumour Biol; 2009; 30(4):221-31. PubMed ID: 19776674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IgG and FcγR genotypes and humoral immunity to mucin 1 in prostate cancer.
    Pandey JP; Namboodiri AM; Kistner-Griffin E
    Hum Immunol; 2013 Aug; 74(8):1030-3. PubMed ID: 23619475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.